
Nutra Pharma Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 IR@nutrapharma.com April 10, 2018-- Coral Springs, Florida-- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced todaythat they have filed a new provisional patent to pr